Tonghua Dongbao cooperates with Suzhou Zhonghe to develop GLP-1

Tonghua Dongbao signed a "technology development contract" with Suzhou Zhonghe Biomedical Technology Co., Ltd., which will entrust the latter with the research and development of GLP-1 fusion protein production process, and intends to break the situation of single insulin variety line and upgrade the diabetes product line Recombinant human insulin is the main product of Tonghua Dongbao According to the company, the development of this product enriches the company's diabetes drug variety and improves the level of diabetes drug According to the public information, GLP-1 is a new diabetes drug with a new mechanism after insulin and small molecule hypoglycemic drugs At present, only Shiguibao and AstraZeneca's exenatide and Novo Nordisk's lilalutide have been approved The product Tonghua Dongbao cooperates to develop is dulaglutide, a new diabetes drug that Lilly is applying for Data show that dulaglutide is superior to exenatide in terms of hypoglycemic effect and weight loss, with fewer side effects It is expected to become another blockbuster in GLP-1 analogues in the future At present, Lilly dulaglutide has completed the clinical phase III and is waiting for FDA approval The information disclosed by the entrusting party Zhonghe biology in January this year also gives a detailed introduction to the research and development process of the drug The drug is currently in the stage of small trial research It is expected to complete the pre clinical research by the end of 2015, submit the application for clinical approval, obtain the clinical approval in 2016, apply for the production approval in 2021, and put the product on the market in 2022 It is worth mentioning that at present, there are many domestic imitations of the drug, and Zhejiang Huayang pharmaceutical has been accepted by CDE for the clinical application of the variety